(lp0
S"Neurocrine Outperforms Even Bullish Estimates Of Ingrezza Approval Upside Benzinga - Apr 12, 2017 Shares of Neurocrine Biosciences, Inc.  soared by more than 20 percent Wednesday after the U.S. Food and Drug Administration granted approval for the company's Ingrezza therapy.Neurocrine Announces FDA Approval of INGREZZA TM  Capsules as the ... - PR Newswire Why Neurocrine Biosciences Stock Is Soaring Higher Today - Motley Fool"
p1
aS'Neurocrine Biosciences, Inc.  Is Making A Strong Argument Through Its ... NY Stock News - 15 hours ago The technicals for Neurocrine Biosciences, Inc.  has spoken via its technical chart and the message is loud and clear.'
p2
aS"Ingrezza Label Gives Neurocrine A Competitive Edge Seeking Alpha - Apr 13, 2017 It has been over 20 years in the making, but Neurocrine  finally received US approval for its first product, Ingrezza, for treating tardive dyskinesia.Neurocrine's Stock Up, FDA Nod for Tardive Dyskinesia Drug - Yahoo Finance1st drug OK'd for movement disorder caused by certain meds - CNSNews.com"
p3
aS"Neurocrine Biosciences Inc. closed with a change of 3.07% in the Previous ... Free Observer - 21 hours ago If you look at the company's income statement over the past years, you will see that the company is constantly posting gross profit: In 2014, NBIX earned gross profit of 0, in 2015 0 gross profit, while in 2016 Neurocrine Biosciences Inc. (NBIX ...Featured Stock: Neurocrine Biosciences Inc.  - HugoPressNeurocrine Biosciences, Inc.  Stock Rating Reaffirmed by Robert W. Baird - BNB Daily "
p4
aS'Neurocrine Announces American Journal of Psychiatry Publication of Positive ... PR Newswire  - Mar 21, 2017 SAN DIEGO, March 21, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. , a biotechnology company focused on neurologic, psychiatric and endocrine related disorders, announced today that positive results from the Kinect 3 Phase III&nbsp;...An End-of-Day Technical Review: Neurocrine Biosciences, Inc. , Hancock ... - Post AnalystNeurocrine Biosciences, Inc.  Advances 2.07% in Pre-market - Benchmark Monitor'
p5
aS'Company Outlook on Neurocrine Biosciences, Inc.  : Analyst ... The Herald - 17 hours ago Out of the 12 covering sell-side analysts giving share ratings for Neurocrine Biosciences, Inc. , 10 have pegged the stock as a Strong Buy while 1 analysts have rated the stock a Buy.'
p6
aS"Today's Research Reports on Stocks to Watch: Teva Pharmaceutical and ... Yahoo Finance - Apr 5, 2017 NEW YORK, NY / ACCESSWIRE / April 5, 2017 / Teva Pharmaceutical Industries and Neurocrine Biosciences will be racing for the FDA approval for their treatments of tardive dyskinesia, revealed an analyst on Tuesday.Teva Huntington's treatment, Austedo, wins FDA approval - BioWorld OnlineTeva Gets Good News but Still Needs a Head - Barron's"
p7
aS'AbbVie , Neurocrine Biosciences  Report Positive Phase 2b Data ... StreetInsider.com - Apr 7, 2017 AbbVie , a global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. , today announced detailed results from a Phase 2b clinical trial evaluating the efficacy and safety of elagolix alone or in&nbsp;...AbbVie  and Neurocrine Bio  Post Promising Phase 2b Results - Economic CalendarAbbVie  Slips on Test Results - Baystreet.ca'
p8
aS'Neurocrine Biosciences Inc.  Moves Lower on Volume Spike for April 05 Equities.com - Apr 5, 2017 Neurocrine Biosciences Inc.  traded on unusually high volume on Apr. 05, as the stock lost 5.9% to close at $40.67. On the day, Neurocrine Biosciences Inc. saw 1.32 million shares trade hands on 12,561 trades. Considering that the stock averages&nbsp;...Jefferies Group LLC Reaffirms Buy Rating for Neurocrine Biosciences, Inc.  - The Cerbat GemSomewhat Positive News Coverage Likely to Impact Neurocrine Biosciences (NBIX ... - Sports Perspectives'
p9
aS'Is There Momentum to Neurocrine Biosciences Inc  Rives Journal - Apr 16, 2017 At the time of writing, the 14-day ADX for Neurocrine Biosciences Inc  is standing at 19.28. Many chart analysts believe that an ADX reading over 25 would suggest a strong trend.'
p10
a.